These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma.
    Author: Roch N, Kutup A, Vashist Y, Yekebas E, Kalinin V, Izbicki JR.
    Journal: Anticancer Res; 2010 May; 30(5):1617-23. PubMed ID: 20592351.
    Abstract:
    Melanoma antigen (MAGE)-A derived peptides are tumour-specific and induce a strong in vitro T-cell response, if presented with human leukocyte antigen (HLA) molecules, which are involved in T-cell-mediated immune surveillance. MAGE-A-derived peptides are recognised by autologous cytotoxic T lymphocytes. The MAGE-A expression profile of hepatocellular carcinomas (HCC) was analysed by PCR assay covering MAGE-A transcripts in 13 patients. MAGE-A peptide expression was determined using a reverse transcription-PCR method. Cryostat sections were stained with monoclonal antibodies directed against HLA class I molecules. Twelve (92.3%) out of thirteen tumours expressed one MAGE-A gene. In at least 90% of the tumours, one MAGE-A peptide was expressed. Determination of the HLA status of the tumours showed a significant loss in approximately 40% of the tumours. The tumour-specific expression of MAGE genes and antigens encoded by a MAGE-family gene may represent useful targets for tumour-specific immunotherapy in HCC patients, in addition to established treatment options.
    [Abstract] [Full Text] [Related] [New Search]